Diagnosis of distal 22q11.2 deletion syndrome in a patient with a teratoid/rhabdoid tumour.

Eur J Med Genet

Central and Southern Genetic Services, Wellington Hospital, Private Bag 7902, Wellington, New Zealand.

Published: September 2011

We report an 18 year old patient with mild intellectual disability who was diagnosed with a late onset teratoid/rhabdoid tumour by histological and immunohistochemical studies. Array-CGH studies, performed on a peripheral blood sample, showed a 3.4Mb deletion of chromosome 22q11.2, distal to the common DiGeorge syndrome (DGS) or Velocardiofacial syndrome (VCFs) region. This deletion is consistent with a diagnosis of distal 22q11.2 deletion syndrome. The deletion encompasses the INI1/SMARCB1 tumour suppressor gene. Biallelic inactivation of this gene is characteristic of atypical teratoid/rhabdoid tumours. Although several constitutional chromosome conditions are known to have increased susceptibility to various forms of cancer, very little is known regarding the magnitude of risk for malignancy associated with distal 22q11.2 deletion syndrome. In view of this finding we suggest that patients diagnosed with distal 22q11.2 deletion syndrome undergo careful prolonged monitoring for this type of tumour. This case demonstrates the need to carefully assess regions found to be deleted in individuals, referred for dysmorphia and/or developments delay, by array-CGH for the presence of genes known to be implicated in malignancy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmg.2010.12.007DOI Listing

Publication Analysis

Top Keywords

distal 22q112
16
22q112 deletion
16
deletion syndrome
16
diagnosis distal
8
teratoid/rhabdoid tumour
8
deletion
7
syndrome
6
22q112
5
syndrome patient
4
patient teratoid/rhabdoid
4

Similar Publications

Article Synopsis
  • - Chronic myeloid leukaemia (CML) cells feature a small chromosome 22 due to a translocation of most of its q arm to chromosome 9.
  • - The researcher used cell hybrids with different parts of chromosome 22 to locate the c-sis oncogene, which is known to be on chromosome 22.
  • - Findings indicate that the c-sis oncogene is located between the CML breakpoint (22q112) and 22q13, confirming its translocation to chromosome 9 in CML cells.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!